This review's purpose is to describe for the practicing clinician the current knowledge about patient compliance to cholesterol-altering drugs and about procedures for compliance management applicable to clinical practice in the United States.
Compliance is defined for four commonly measured major steps and, based on recent electronic monitoring data, for three quantitative categories of active medicationtaking.
The concepts and definition of compliance are undergoing evolutionary changes due to the measurement and availability of new dimensions through electronic monitoring of patient compliance.
Substantial non-compliance to cholesterol-altering drugs has been reported in nine large clinical trials for primary and secondary prevention of coronary heart disease, in two HMOs, and, using electronic monitoring of compliance, in one clinical trial and a selected practice.
The risks of treatment discontinuation increased continuously during treatment and totaled from 6 to 30% after 5 years.
Patterns of day-to-day partial compliance are emerging. (...)
Mots-clés Pascal : Cholestérol, Relation médecin malade, Chimiothérapie, Observance médicamenteuse, Facteur risque, Epidémiologie, Education santé, Homme, Efficacité traitement, Métabolisme pathologie, Hyperlipémie
Mots-clés Pascal anglais : Cholesterol, Physician patient relation, Chemotherapy, Drug compliance, Risk factor, Epidemiology, Health education, Human, Treatment efficiency, Metabolic diseases, Hyperlipemia
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0299510
Code Inist : 002B22A. Création : 15/07/1997.